Dow Jones 30 Stocks SEC Filings — October 26, 2026

Chairman/CEO sold 35,000 shares at $163.09 (~$5.71M) after exercising 35,000 options at $78.52 (~$2.75M); retains 55,390 shares, so the sale is a partial monetization of option gains rather than a full exit

Three insiders (CEO, CHRO, and Health Care executive) sold a combined ~$6.4M in a single window at $160-163, a clustered selling pattern that warrants monitoring

Health Care executive sold 4,331 shares at $161.27 (~$698K), retaining 46,792 shares; a meaningful but modest position reduction

Chief Human Resources Officer sold 4,181 shares at $160.71 (~$672K), retaining 11,295 shares, roughly a 27% reduction of the disclosed position by value of shares sold

Chief Administrative Officer sold 183 shares at $890.03 (~$163K) and 67 shares at $890.85 (~$59.7K), retaining 10,710 shares; trading size is small relative to holdings and low materiality

13F-HR shows Protagonist Therapeutics as the dominant reported position (~$345.07M), indicating high concentration in a single biotech holding

15 disclosed positions with discretionary sole voting authority across most holdings, implying active, decentralized venture decision-making rather than passive exposure

Three senior officers sold ~$6.4M combined at $160-163 within the same reporting window; clustered sales by the Chairman/CEO, CHRO, and a Health Care executive can signal reduced management conviction at current valuation levels

The Chairman/CEO sold 35,000 shares (~$5.71M) immediately after exercising 35,000 options at $78.52; the net economic gain is large and the sale is the most material single transaction in the filing set (materiality 9/10)

Chief Administrative Officer sold ~250 shares total across two trades at ~$890 (~$223K combined); low dollar amount, but a sell-only pattern at an elevated share price warrants noting

Protagonist Therapeutics represents the bulk of the reported 13F value, creating single-name concentration risk for the JJDC venture portfolio; early-stage biotech exposure is inherently volatile

The 13F shows Standard BioTools (311,967 shares) with zero sole voting authority and no shared or other-manager authority, an unusual disclosure inconsistency that could indicate a reporting error or non-discretionary holding requiring verification

Very small positions such as Adicet Bio (~$0.16M) and VOR Biopharma (~$1.03M) add complexity without meaningful capital impact, and may reflect exited or residual holdings

No period-over-period financials, guidance, capital allocation, or scheduled-event data were supplied, so risk assessment on fundamentals (margins, leverage, dividends, buybacks) cannot be made for any of the five filings

Insider sales clustered at $160-163; if the stock stays in this range, the selling may be routine diversification rather than a fundamental signal, creating a potential entry point if fundamentals hold up on the next earnings release

The CEO's exercise at $78.52 against a ~$163 sale price implies a ~107% gain on exercised options, meaning management's cost basis is low and sales may be partly tax- and diversification-driven rather than a deterioration signal; this context supports a less bearish reading

The JJDC 13F's largest disclosed position (~$345.07M) gives a clear read-through on where JNJ's venture arm sees the highest-conviction early-stage value; monitoring Protagonist clinical and partnership milestones provides a thesis-linked catalyst

The 13F's breadth across 15 biotech and medtech names (including MeiraGTx ~$73.05M and Contineum ~$26.56M) offers a diversified signal set for tracking JNJ's strategic pipeline interests ahead of Q4 disclosures

Goldman's executive sales are small (~$223K) relative to share count held, so the low-materiality insider selling does not offset any broader positive setup; the stock may be less exposed to insider-sentiment risk than P&G

P&G shows broad-based selling while Goldman shows only minor selling; relative insider sentiment favors Goldman on this data, though neither set of filings contains enough fundamental context to act on

Procter & Gamble accounts for all four Form 4 filings and the bulk of insider dollar volume (~$6.4M across three officers), concentrated in a ~$160-163 price band; this single-company concentration limits the ability to draw sector-level conclusions from the stream

The P&G CEO's option exercise at $78.52 followed by a sale at $163.09 reflects a common executive compensation monetization pattern; where options are deep in the money, sell-side insider activity is often diversification rather than a directional bet

J&J's 13F shows a concentrated early-stage biotech/medtech book with one dominant position (Protagonist) and a long tail of smaller holdings; this structure is typical of corporate venture arms seeking strategic optionality rather than financial returns

Only the 13F filing carries portfolio-level holdings data, and none of the five filings include period-over-period financials, guidance, or capital allocation data; sector-level trend analysis is not supportable from this batch

Monitor for additional Form 4 filings from the Chairman/CEO, CHRO, and Health Care executive to confirm whether the clustered selling continues beyond this window; watch the next earnings release for any guidance commentary that explains the sales [date not provided]

Track remaining option expirations and exercise activity for the CEO, since further exercise-and-sell events would reinforce the monetization pattern [date not provided]

Compare the next quarterly 13F (quarter ending December 31, 2026) against this filing to assess changes in Protagonist, MeiraGTx, and Contineum positions, since no prior-period comparison is available in this batch [expected Q1 2027]

Verify the zero sole-voting-authority entry for the 311,967-share Standard BioTools position, as correction or clarification in an amendment (13F-HR/A) would be material to the accuracy of the portfolio record [date not provided]

Watch for further sales by the Chief Administrative Officer; repeated small sales at elevated prices would be a more meaningful pattern than the single-day trades in this filing [date not provided]

Confirm whether financial period comparisons, guidance, and scheduled-event data are available for the Dow 30 constituents in the next brief, since the current batch cannot support the portfolio-level margin, growth, or capital allocation analysis the stream is designed for [next brief]